Overview
Company Does Not Provide H-1B Sponsorship
TandemAI provides a cloud-based platform for pre-clinical drug discovery called TandemViz. It serves researchers at pharmaceutical companies and academic institutions by offering a suite of computational tools, AI, and supercomputing to simulate how drugs interact with proteins at the molecular level. The platform is accessed through a web interface, where users run dynamic physics-based molecular simulations to visualize drug-protein interactions and generate predictive models for efficacy and safety. TandemAI differentiates itself by offering a Discovery as a Service model that makes advanced drug-discovery tools widely accessible through subscriptions and service contracts, combining expertise from data science, physics, biology, and chemistry to speed up the research process. The company's goal is to democratize access to advanced computational tools, accelerate the discovery of therapeutic candidates, and improve the success rate of pre-clinical studies for patients in need.
Work here?Claim your company
Simplify's take
What believers are saying
- June 10, 2026, Third Rock delivered a candidate in under 18 months.
- TandemAI says over 150 biopharmaceutical partners now use its platform globally.
- The November 2025 $22 million extension funded model development and wet-lab expansion.
What critics are saying
- TandemAI still sells services, not approved drugs, so revenue depends on partner demand.
- Insilico and Recursion outspend TandemAI on datasets, automation, and clinical programs.
- If a single flagship program fails, TandemAI lacks clinical assets to survive.
What makes Tandem unique
- TandemAI’s 2025 Perpetual merger adds peptide discovery to small-molecule physics workflows.
- TandemViz unifies AI, molecular dynamics, quantum mechanics, and wet-lab data in one workspace.
- The May 19, 2026 Mila partnership deepens world-model research for chemistry.
Help us improve and share your feedback! Did you find this helpful?